Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 2/20 | 0.42 |
| ▸ | NFKB1 | P19838 | 4/20 | 0.40 |
| ▸ | NFKB2 | Q00653 | 4/20 | 0.40 |
| ▸ | RELA | Q04206 | 4/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 2/20 | 0.39 |
| ▸ | CA2 | P00918 | 2/20 | 0.39 |
| ▸ | BTK | Q06187 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 3/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.36 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.36 |
| ▸ | CA7 | P43166 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20147716 | 0.86 | CTSK (0.40) | CTSKNFKB1NFKB2RELAHRH3 | |
| SCHEMBL12026396 | 0.85 | CTSK (0.50) | CTSKNFKB1NFKB2RELAHRH3 | |
| SCHEMBL14820382 | 0.81 | CTSK (0.45) | CTSKNFKB1NFKB2RELAHRH3 | |
| SCHEMBL20626705 | 0.80 | CTSK (0.40) | CTSKNFKB1NFKB2RELAHRH3 | |
| SCHEMBL14577548 | 0.79 | CTSK (0.44) | CTSKNFKB1NFKB2RELAHRH3 | |
| SCHEMBL14806562 | 0.79 | CTSK (0.44) | CTSKNFKB1NFKB2RELAHRH3 | |
| SCHEMBL25872149 | 0.78 | CTSK (0.39) | CTSKNFKB1NFKB2RELAHRH3 | |
| SCHEMBL25497147 | 0.78 | NR1H2 (0.47) | CTSKNFKB1NFKB2RELACA1 | |
| SCHEMBL13016625 | 0.77 | CTSK (0.42) | CTSKNFKB1NFKB2RELAHRH3 | |
| SCHEMBL14024975 | 0.76 | CTSK (0.59) | CTSKHRH3CA1CA2BTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11820767-B2 | Benzyl amine-containing heterocyclic compounds and compositions useful against mycobacterial infection | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2023-11-21 | — | — | US | disclosed |
| US-11820767-B2 | Benzyl amine-containing heterocyclic compounds and compositions useful against mycobacterial infection | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2023-11-21 | — | — | US | disclosed |
| US-20230133132-A1 | NAMPT MODULATORS | CYTOKINETICS, INC. | 2023-05-04 | — | — | US | disclosed |
| US-20170037059-A1 | GYRASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2017-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11820767-B2 | Benzyl amine-containing heterocyclic compounds and compositions useful against mycobacterial infection | BET1, BRD4, BRD3 | CTSK 2323/4885NFKB1 785/4885NFKB2 1700/4885 |
| US-20170037059-A1 | GYRASE INHIBITORS | TOP1, CA7, TOP2B | CTSK 2743/4885NFKB1 2218/4885NFKB2 2654/4885 |
| US-20230133132-A1 | NAMPT MODULATORS | NAMPT, MC4R, SIRT1 | CTSK 3960/4885NFKB1 2063/4885NFKB2 1423/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.